Search

Displaying results 5431 - 5440 of 7018 in total
  1. Drug

    Adenosine-5'-Monophosphate Glucopyranosyl-Monophosphate Ester

    go.drugbank.com/drugs/DB01774
    Experimental

    Serves as the glycosyl donor for formation of bacterial glycogen, amylose in green algae, and amylopectin in higher plants. [PubChem]

  2. Drug

    DCFBC F-18

    go.drugbank.com/drugs/DB14772
    Investigational

    DCFBC F-18 is under investigation in clinical trial NCT02190279 (18F-DCFBC PET/CT in Prostate Cancer).

  3. Drug

    BD-111

    go.drugbank.com/drugs/DB18247
    Investigational

    BD-111 is an HSV-1-erasing lentivirus-like particle delivering gRNA-expressing cassette and SpCas9 mRNA.

  4. Drug

    DT-DEC01

    go.drugbank.com/drugs/DB19433
    Experimental

    DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.

  5. Drug

    HSV-2 theracine

    go.drugbank.com/drugs/DB05811
    Experimental

    HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.

  6. Drug

    Asoprisnil

    go.drugbank.com/drugs/DB06680
    Investigational

    Asoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.

  7. Drug

    ADC4022

    go.drugbank.com/drugs/DB05195
    Investigational

    ADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.

  8. Drug

    Chlorfenson

    go.drugbank.com/drugs/DB05377
    Experimental

    Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

  9. Drug

    RTN-001

    go.drugbank.com/drugs/DB05615
    Investigational

    SLx-2101 is an oral, long-acting PDE5 inhibitor developed by Surface Logix Inc. to treat Hypertension.

  10. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available. … enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a